| Autor: |
Abdulsattar, Sura A., Alkhader, Raghd A. Y., Mohammed Saeed, Haider Ridha, AlKazazz, Fatin F. |
| Předmět: |
|
| Zdroj: |
Medico-Legal Update; Jan-Mar2021, Vol. 21 Issue 1, p1012-1017, 6p |
| Abstrakt: |
Hepatotoxicity disorders are relatively common in patients with inflammatory bowel disease that includes ulcerative colitis and Crohn's disease. Abnormal serum liver functions tests can develop during treatment with (TNF-α) blocking agents, such as, Infliximab. The aim of this review is to clarify the role of infliximab in the development of liver enzyme abnormalities in patients with Crohn's disease. The most common presentation of infliximab-associated liver injury is a hepatocellular type with auto-immune features, marked by increased serum aminotransferases levels. Cholestatic injury is much less common, and marked by jaundice and increased serum ALP and bilirubin levels, with elevations of serum ALT and AST. Abnormalities of liver function tests in sera of patients with Crohn's disease typically resolve after discontinuation of infliximab, although sever liver injury leading to liver transplant cannot be ruled out. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
